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General practice vs surgical-based follow-up for patients with
colon cancer: randomised controlled trial
DA Wattchow1, DP Weller*,2, A Esterman3, LS Pilotto4, K McGorm2, Z Hammett4, C Platell5 and C Silagy{
1Department of Surgery, Flinders University, Adelaide, 5042 South Australia; 2Division of Community Health Sciences – General Practice, University of
Edinburgh, 20 West Richmond St, Edinburgh, Scotland EH8 9DX, UK; 3Division of Health Sciences, University of South Australia, Adelaide, 5000, South
Australia; 4Department of General Practice and Flinders Centre for Epidemiology & Biostatistics, Flinders University, Adelaide, 5042 South Australia;
5Department of Surgery, Fremantle Hospital, Fremantle, 6160 Western Australia
This trial examined the optimal setting for follow-up of patients after treatment for colon cancer by either general practitioners or
surgeons. In all, 203 consenting patients who had undergone potentially curative treatment for colon cancer were randomised to
follow-up by general practitioners or surgeons. Follow-up guidance recommended three monthly clinical review and annual faecal
occult blood tests (FOBT) and were identical in both study arms. Primary outcome measures (measured at baseline, 12 and 24
months were (1) quality of life, SF-12; physical and mental component scores, (2) anxiety and depression: Hospital Anxiety and
Depression Scale and (3) patient satisfaction: Patient Visit-Specific Questionnaire. Secondary outcomes (at 24 months) were:
investigations, number and timing of recurrences and deaths. In all, 170 patients were available for follow-up at 12 months and 157 at
24 months. At 12 and 24 months there were no differences in scores for quality of life (physical component score, P¼ 0.88 at 12
months; P¼ 0.28 at 24 months: mental component score, P¼ 0.51, P¼ 0.47; adjusted), anxiety (P¼ 0.72; P¼ 0.11) depression
(P¼ 0.28; P¼ 0.80) or patient satisfaction (P¼ 0.06, 24 months). General practitioners ordered more FOBTs than surgeons (rate
ratio 2.4, 95% CI 1.4–4.4), whereas more colonoscopies (rate ratio 0.7, 95% CI 0.5–1.0), and ultrasounds (rate ratio 0.5, 95% CI
0.3–1.0) were undertaken in the surgeon-led group. Results suggest similar recurrence, time to detection and death rates in each
group. Colon cancer patients with follow-up led by surgeons or general practitioners experience similar outcomes, although patterns
of investigation vary.
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Colon cancer is the most common internal malignancy in Australia
and other western countries, and is usually treated surgically, with
or without chemotherapy. Currently follow-up is chiefly conducted
in surgical clinics, aiming to detect treatable recurrent disease and
provide reassurance to patients. Recurrent disease may be detected
through symptoms or signs (most commonly), tests such as
carcino-embryonic antigen (CEA) or faecal occult blood test
(FOBT), radiological evidence or colonoscopy (Sugrue et al, 1991;
Schoemaker et al, 1998; Berman et al, 2000; McFall et al, 2003;
Skaife et al, 2003). Clinical practice guidelines in Australia and the
UK highlight gaps in evidence and recommend colonoscopy every
3 to 5 years; Australian guidance includes annual FOBT (NHMRC,
1999; NICE, 2004).
Despite widespread interest in moving the focus of cancer
follow-up from secondary to primary care, where evidence from
other cancers suggests that it can produce equal or improved
outcomes with potential economic savings (Grunfeld et al, 1996),
there is a lack of evidence examining the setting for postoperative
colon cancer follow-up.
Conversely, systematic analyses of randomised trials suggest a
survival benefit from intensive vs nonintensive follow-up
(although they provide no clear guidance on the best combination
and frequency of visits or investigations) (Bruinvels et al, 1994;
Kievit, 2002; Renehan et al, 2002; Northover, 2003; Pfister et al,
2004; Jeffery et al, 2006). However, pooling of data from these
studies is challenging and the conclusions of meta-analyses have
been questioned (Renehan et al, 2005) – study designs vary widely
in their follow-up patterns, to the extent that some study arms
deemed as ‘intensive’, have the same regimen as ‘standard’ in
others.
Further, outcomes beyond recurrence (such as quality of life)
have infrequently been included in these studies. While a focus on
recurrence, survival and mortality may be justified in trials
comparing follow-up protocols aimed at detecting recurrences,
there is a strong argument that studies comparing site of follow-up
(in which protocol adherence is not enforced) should logically
focus on ‘process of care’ outcomes which can be linked in a
logical way to setting: indeed, there have been calls for more trials
in which the focus shifts from early detection of recurrences
towards quality assessment and patient support (Kievit, 2002).
Hence, setting of follow-up may impact on patient well-being and
satisfaction with care; we hypothesise that while secondary care
may provide rapid access to expertise and investigations, follow-up
in general practice (GP) may lead to improvements in these
outcomes.
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In response to the identified lack of evidence examining setting
of cancer follow-up, we report a randomised controlled trial
comparing outcomes in GP-led and surgeon-led follow-up arms in
patients treated for colorectal cancer. The objective of the study
was to determine whether, among these patients, the setting of
follow-up impacts on our primary outcomes: quality of life,
psychological well-being and satisfaction with care. Also, recorded
were the follow-up procedures undertaken in the two arms, and
data on recurrences and death.
METHODS
Study design
The study was a multicentre, randomised controlled trial, which
recruited patients from hospitals in South Australia, Victoria,
Western Australia and Northern Territory. Potentially eligible
patients were identified by direct referral from participating
surgical staff, theatre and histopathology reports, cancer registries
and outpatient lists. Recruitment began in March 1998 and ceased
March 2001. Two-year follow up for the study sample was
completed in April 2003. Ethical approval was obtained from the
all institutional ethics committees of participating centres.
Approval was also gained from the Ethics Committee of the
Australian Institute of Health and Welfare. Participant consent
included permission to obtain data on deaths/recurrences from
state and national databases.
Inclusion criteria
 Surgery for colon cancer (including rectosigmoid) with
histological grade Dukes stage A, B or C (cases of disseminated
cancer were excluded).
 Completion of postsurgical chemotherapy (principally Dukes
Stage C patients).
 Follow-up by GPs and surgeons available.
 Able to provide informed consent.
Exclusion criteria
 Rectal tumours (current practice for rectal cancer follow-up
requires regular sigmoidoscopy which would not be undertaken
by many GPs).
 Significant polyps discovered at initial colonoscopy (or at
subsequent completion colonoscopy) that indicated increased
frequency of colonoscopic monitoring.
 Any other condition that warranted increased intensity of
surveillance with respect of colon cancer follow-up.
Following agreement from the treating surgeon and GP, eligible
patients were invited to participate in the study at their final
postsurgical follow-up visit (4– 6 weeks after surgery or comple-
tion of postsurgical chemotherapy). Consenting patients were then
randomly allocated to either ‘GP-led’ or ‘surgeon-led’ follow-up
using an Excel random number generator. Randomisation was
conducted by the study researchers, who were not involved in the
design of the study or the clinical care of the patients, and was
concealed until the interventions were assigned. The study was
single-blinded. Researchers at all times were unaware of the patient
allocation until after the randomisation process. Patients were
reviewed by GPs in their practice rooms and surgeons in their
surgical clinics.
Interventions
The setting and environment of follow-up (primary vs secondary
care) constituted our intervention. Follow-up guidance, based on
current clinical practice and guidance (Table 1) was provided, and
inserted into either the patient’s GP or surgeon/hospital records.
Nevertheless, in accordance with the study’s pragmatic design,
there was no compulsion for clinicians in either setting to adhere
to the guidance. Participating clinicians received regular study
information from contact with the study researcher and a
newsletter. Patients allocated to ‘GP-led’ follow-up could be
referred back to surgical clinics at any point in the study;
similarly, patients in the ‘surgeon-led’ follow-up group could
consult their GP at any time during the course of the study.
Outcome measurement
The study used validated outcome measures; self-completion
questionnaires which included a range of validated instruments
(below) were developed and piloted among colorectal cancer
patients treated at Flinders Medical Centre. Instruments were
provided directly to patients in clinic settings or sent by post.
Clinical data were obtained through GP and hospital case note
audit, using a standardised data extraction sheet at 12 and 24
months postrecruitment. Cancer incidence and deaths were
determined through data linkage with state-based cancer registries
and the National Death Index (AIHW, 2004).
Primary outcomes Measured at baseline, 12 and 24 months
 quality of life based on SF-12 Physical (PCS) and mental health
component (MCS) scores (Ware et al, 1995),
 depression and anxiety based on the Hospital Anxiety and
Depression Scale (HADS) (Zigmond and Snaith, 1983).
Measured at 24 months only:
 Satisfaction based on the Patient Visit-Specific Questionnaire
(PSVQ) (Davies and Ware, 1991).
Secondary outcomes Measured at 24 months only:
 the number and type of investigations (blood tests, FOBT,
colonoscopies and radiological investigations),
Table 1 Recommended follow-up regimen (5 years in total)
The patient should be reviewed
1. Three monthly for the first 2 years postoperatively
2. Then 6 monthly for the next 3 years
Patient history
Please ask the following (or similar) questions to your patient
1. What is your bowel habit? Has there been any change lately?
2. Have you noticed any bleeding in the stools or from the anus?
3. Have you experienced any abdominal pains of more than a few days’
duration?
4. Have you experienced any other pains, for example in your back, chest or
legs?
5. Have you noticed any weight loss?
6. Have you been feeling tired or lethargic?
Physical examination
Assess the patient for
1. Colour
2. Enlarged neck nodes
3. Abdominal masses, for example, the liver, wound deposits or ascites
Diagnostic tests
Recent studies have raised doubts as to the value of many diagnostic tests in the
detection of recurrent or metastatic disease. However, there is value in
performing.
1. Annual FOBT (faecal occult blood test)
2. A colonoscopy every 3 years
Note: If the patient experiences any positive signs or symptoms, they should be
appropriately investigated. Please use the case note provided for each relevant
follow-up consultation.
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 number and time to detection of recurrences,
 deaths from all causes at 2 years postentry into the study.
Sample size and statistical analysis
All power calculations were undertaken using a power of 80% with
a 0.05 two-sided significance level. Power calculations were based
on our primary outcome measures.
SF-12: A sample size of 64 in each group was required to detect a
difference in mean PCS or MCS score of 5 at 24 months, assuming
a standard deviation of 10, using a two group t-test.
HADS: A sample size of 64 in each group was required to detect
a difference in mean HADS Anxiety or Depression score of 1.5
at 24 months, assuming a standard deviation of 3.0, and using a
two group t-test.
PSVQ: A sample size of 62 in each group was required to detect a
difference of 20% in the proportion rating an item as ‘excellent’ or
‘very good’ 24 months (90% in one group compared with 70% in
the other).
Allowing for a dropout rate of 25%, we set our recruitment
target at 100 patients in each treatment arm. The study was not
powered to measure differences in recurrence and mortality data at
24 months follow-up. These data are nevertheless analysed and
reported, and recording of recurrence and mortality in study
participants is on going.
Unadjusted comparisons between the two treatment arms for
the HADS and SF-12 scales at 12 and 24 months were undertaken
using Exact Mann–Whitney U-tests. Comparisons adjusting for
baseline values were undertaken using analysis of covariance on
ranks. The percentage satisfied or very satisfied on PSVQ items
were compared in the two treatment arms using Fisher’s exact tests
at 12 and 24 months. Rates of investigations undertaken,
recurrences and deaths per months on trial were compared using
Fisher’s exact tests. Time to recurrence and death were analysed
using a Kaplan–Meier analysis with Log rank test. Trial
participants and patients in the SA Cancer Registry were compared
using w2-tests. Although randomisation was by individual, there
was concern that results might be clustered by hospital or surgeon.
For the counts of investigations a random effects Poisson
regression model was fitted to establish whether or not observa-
tions could be considered independent by comparing with a usual
Poisson regression model. The analysis showed virtually no
difference between the models and therefore observations were
considered to be independent.
Double data-entry was used and analysis was blinded, on an
intention-to-treat basis.
RESULTS
Participant flow
Figure 1 shows the flow of participants through the study. Of the
611 patients assessed, 340 were eligible, and 203 agreed to
randomisation. The main reason for patients declining participa-
tion (137) was a desire for the choice over setting for follow-up to
be made either by themselves or their surgeon. Withdrawal was
viewed as noncompletion of questionnaires (primary outcome
measures) – data on deaths were still collected. Reasons given for
withdrawing were participant commitment (10), concern over the
time involved (4), lack of understanding of the study (1) and one
did not ‘wish to be reminded of their illness’. The remaining
patients gave no explanation, but the withdrawals were equally
distributed between the groups. There were 76 patients in the GP
group, and 81 in the surgical group after 24 months of follow-up,
meeting the numbers required for statistical validity. Analysis was
on an ‘intention to treat’ basis.
Table 2 shows the characteristics of the trial participants at
baseline. Of patients, 70% were recruited in SA. Groups had similar
characteristics with the exception of education, where there was a
trend towards higher levels of education in the surgeon follow-up
group. To examine external validity of our sample we compared
age, sex and Dukes staging with SA Cancer Registry data (Cancer
Council of SA, 2001) (included in Table 2) using w2-tests. Study
participants did not differ significantly compared with registry
patients with respect to gender (P¼ 0.53) and Dukes staging
(P¼ 0.12), but had a slightly narrower age distribution (P¼ 0.05).
Depression and anxiety (Table 3)
A HADS score of 8 –10 is borderline and 11–21 abnormal. There
were no statistically significant differences between the two groups
at either 12 or 24 months follow-up and, on average, study
participants were in the normal range at all times.
Quality of life (Table 3)
A score of 50 on the SF12 scale is normal for the Australian
population (a difference of 10 points is clinically significant).
Patients in our study had reduced subjective quality of life with
respect to physical health at baseline and this improved as the
study progressed. Comparison of scores in the two arms of the
study revealed no statistically significant differences after 12 or 24
months of follow-up.
Patient satisfaction (Table 4)
There were no statistically significant differences between study
groups in the percentage of patients rating each item ‘excellent’ or
‘very good’ on the PSVQ scale, administered at 24 months, and
with the exception of ‘contacting the doctor by telephone’ and
‘time spent in the waiting room’, the combined study group
reported high levels of satisfaction with their care.
Follow-up visits and investigations (Table 5)
Patients in both groups were expected to visit their treating
clinician for follow-up on a quarterly basis. In the GP follow-up
group, patients visited their GP on average 1.27 times per quarter
Patients randomised
(N = 203)
Surgeon follow-up
(N = 106)
Surgeon follow-up
(N = 88)
Surgeon follow-up
(N = 81)
GP follow-upBaseline
12 months
24 months
LFU=lost to follow-up
13 withdrew/LFU
2 died
13 withdrew/LFU
5 died
0 withdrew/LFU
6 died
1 withdrew/LFU
6 died
(N = 97)
GP follow-up
(N = 82)
GP follow-up
(N = 76)
Figure 1 Patient flow through study.
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(718 visits over 565 patient– months on trial). Those in the surgeon
follow-up group visited the surgeon on average 0.84 times per
quarter (457 visits over 543 patient–months on trial).
Patients in the GP-led follow-up arm were significantly more
likely to have one or more FOBTs, whereas patients in the surgeon-
led follow-up arm were significantly more likely to have one or
Table 2 Characteristics of colon cancer patients: Study+South Australian population
Study participants (n¼ 203) South Australian Cancer registry 1995 to 2002
GP Surgeon Total
n % n % n % n %
State
SA 73 75.3 69 65.1 142 70.0
NT 0 .0 1 .9 1 .5
WA 10 10.3 21 19.8 31 15.3
VIC 14 14.4 15 14.2 29 14.3
Gender
Male 60 61.9 57 53.8 117 57.6 Male 786 51.1
Female 37 38.1 49 46.2 86 42.4 Female 752 48.9
Total 97 100.0 106 100.0 203 100.0 Total 1538 100.0
Age group
o60 10 10.3 16 15.1 26 12.8 o60 258 16.8
60–69 18 18.6 28 26.4 46 22.7 60–69 368 23.9
70–79 47 48.5 46 43.4 93 45.8 70–79 555 36.1
80+ 22 22.7 16 15.1 38 18.7 80+ 357 23.2
Total 97 100.0 106 100.0 203 100.0 Total 1538 100.0
Education
Primary only 26 27.7 16 15.7 42 21.4
Secondary 28 29.8 19 18.6 47 24.0
School leaver 16 17.0 26 25.5 42 21.4
Postsecondary 8 8.5 23 22.5 31 15.8
Unknown 16 17.0 18 17.6 34 17.3
Total 94 100.0 102 100.0 196 100.0
Dukes stage
A 24 24.7 23 21.7 47 23.2 A 273 17.7
B 43 44.3 53 50.0 96 47.3 B 733 47.6
C 30 30.9 30 28.3 60 29.6 C 532 34.6
Total 97 100.0 106 100.0 203 100.0 Total 1538 100.0
Table 3 HADS and SF-12 scores
GP Surgeon Significance
Outcome n* median IQR n* median IQR unadjusteda adjustedb
HADS anxiety
Baseline 95 4.0 5.0 106 4.0 4.0
12 months 81 4.0 3.5 87 4.0 4.0 0.932 0.716
24 months 76 4.0 5.0 81 5.0 4.5 0.440 0.106
HADS depression
Baseline 97 4.0 5.0 106 3.0 4.0
12 months 81 4.0 4.0 87 4.0 5.0 0.213 0.283
24 months 76 4.0 5.0 81 3.0 4.0 0.540 0.796
SF-12 PCS
Baseline 95 42.3 20.5 105 40.5 19.0
12 months 82 49.3 11.2 88 55.9 14.3 0.576 0.887
24 months 76 48.5 17.7 79 50.4 14.4 0.194 0.279
SF-12 MCS
Baseline 95 55.0 12.9 105 55.1 14.5
12 months 81 49.9 13.0 88 55.6 10.8 0.558 0.510
24 months 74 54.4 11.8 79 55.9 11.2 0.448 0.474
*Not all participants identified as ‘available for follow-up’ (Figure 1) completed every instrument. aMann–Whitney U-test. bAdjusted for baseline value using analysis of covariance
on ranks.
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more ultrasounds, and one or more colonoscopies. We recorded,
during the study period, the numbers of colonoscopies performed
in response to development of symptoms (change in bowel habit
or bleeding) or positive FOBT. Such indications existed in 32
patients in the GP group and 38 patients in the surgical group
(Fisher’s exact test P¼ 0.30).
Recurrence and death
The study was not powered to detect differences in death or
recurrence rates; nevertheless, no clear trends emerged. The
recurrence rate in the GP follow-up group was 7.1 per 1000 months
on trial compared with 8.0 per 1000 months on trial in the surgeon
follow-up group (Fisher’s exact test P¼ 0.92). For those with a
recurrence, the median time to detection was 9.5 months from
recruitment for the GP follow-up group, and 8.0 months for the
surgeon follow-up group. A Kaplan– Meier survival analysis was
undertaken and a Log rank test found there to be no difference in
time to recurrence between study groups (P¼ 0.76).
The death rate in the GP follow-up group was 6.6 per 1000
months of follow-up compared with 5.4 per 1000 months of follow-
up in the surgeon follow-up group (Fisher’s exact test P¼ 0.67).
For those with who died, the median time to death was 31 months
for the GP follow-up group, and 20 months for the surgeon follow-
up group. A Kaplan– Meier survival analysis was again undertaken
and a Log rank test found there to be no significant difference in
time to death between study groups (P¼ 0.69).
DISCUSSION
We found no significant differences between postsurgical colon
cancer patients undergoing either GP-led or surgeon-led follow-up
for our primary outcome measures of quality of life, depression
and anxiety and patient satisfaction. There were insufficient
numbers to demonstrate differences in number of recurrences
and deaths, but the data do not suggest the emergence of any
trend, and these outcomes will be examined in longer-term follow-
up of our study participants. Although equivalent follow-up
guidance was provided to those involved in the care of study
participants there was a higher rate of FOB testing in the GP-led
follow-up arm and higher numbers of colonoscopies and ultra-
sounds in the surgeon-led arm.
As participants were typical of a western population with a high
incidence of colorectal cancer, the findings of the study are
generalisable to other countries with well-developed systems of
primary care and surgical services.
By issuing identical follow-up guidance to both study arms, our
study sought a best estimate of the effect of setting. It was
pragmatic in design; blinding of trial participants was not
possible after randomisation. Further, there was inevitably a
degree of crossover between the two arms of our study – it was
neither possible nor desirable to limit access to GPs in patients
allocated to the surgical arm of the study or vica versa. However,
participants largely adhered to their allocated follow-up
groups. The study relied on self-completion questionnaires and
case-note audit for much of its data, involving a significant
response burden, but numbers of questionnaires with missing
data were low at all stages of follow-up. GP and hospital case-notes
are not always complete, and missing data can distort the results
of audit-based studies (Wilson et al, 2000; van Walraven
and Demers, 2001). Nevertheless, the information we required
from case notes was quite straightforward, and generally very
accessible. Further, the standardised data extraction sheets we
developed as part of the study helped ensure accuracy and
consistency.
Table 4 PSVQ at 24 months follow-up – those rating items as ‘excellent’ or ‘very good’
GP (n¼76) Surgeon (n¼ 81)
PSVQ Item n % n % Sig.a
How long they waits for an appointment 60 82.2 60 82.2 0.690
Convenience of location 61 83.6 57 78.1 0.179
Getting through to Doctor by phone 50 68.5 45 61.6 0.257
Time in waiting room to see Doctor 41 56.2 43 58.9 1.000
Average time spent with Doctor 56 76.7 50 68.5 0.116
Explanations of your condition and what has been done for you 61 83.6 59 80.8 0.326
Technical skills of Doctor 65 89.0 66 90.4 0.496
Personal manner of Doctor 71 97.3 69 94.5 0.081
Overall satisfaction with the care from your Doctor 70 95.9 67 91.8 0.064
aFisher’s exact test.
Table 5 Number of patients with one or more of the following pathology and diagnostic tests undertaken per 1000 months on trial
GP (n¼ 97) Surgeon (n¼ 106)
Test Number Rate Number Rate Rate ratio 95% CI for rate ratio sig.a
FOBT 46 23.6 16 9.8 2.4 1.4–4.4 0.003
CEA 33 19.5 48 29.5 0.7 0.4–1.0 0.083
CBP 52 30.7 50 30.7 1.0 0.7–1.5 1.000
LFT 56 33.0 47 28.8 1.1 0.8–1.7 0.556
Xray 30 17.7 20 12.3 1.4 0.8–2.7 0.256
Ultrasound 16 9.4 30 18.4 0.5 0.3–1.0 0.040
CT scan 26 15.3 34 20.9 0.7 0.4–1.3 0.291
Colonoscopy 55 32.4 79 48.5 0.7 0.5–1.0 0.027
Endoscopy 6 3.5 10 6.1 0.6 0.2–1.8 0.408
Sigmoidoscopy 5 2.9 15 8.6 0.3 0.1–1.0 0.051
DRE 19 11.2 28 17.2 0.7 0.3–1.2 0.193
aFisher’s exact test.
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Our study’s finding are consistent with previous research
comparing GP vs hospital follow-up for breast cancer patients
(Grunfeld et al, 1996). They also complement previous studies and
systematic reviews which have examined the intensity of follow-up
regimens for cancers of the large bowel; studies attributing
increased survival to ‘intensive’ follow-up reveal that a substantial
portion of this increase is due to factors other than detection of
treatable disease (Renehan et al, 2005). As comorbid illnesses are
present in the majority of patients with colorectal cancer (Payne
and Meyer, 1995) this may additionally point to the value of
GP-based follow-up.
While many studies have focused on the detection of treatable
disease in the follow-up period our findings provide evidence
regarding patients’ quality of life and satisfaction with care, the
importance of which has been widely recognised. This study
challenges follow-up practices for colon cancer which have
traditionally, in countries such as Australia and the UK, been led
by secondary care. National guidance in these and similar
countries has had little evidence upon which to base recommenda-
tions for setting of follow-up – although UK guidance includes the
use of multidisciplinary teams.
Primary care has a growing role in cancer management
(Campbell et al, 2002). Our conclusions may be strengthened in
the UK by a study of hospital vs GP follow-up, although the results
of this study will not be available for some time, and it differs
inasmuch as diagnostic protocols are not held constant in the two
arms of the study (Primrose et al, 2005). At present there is little
evidence to guide the development of follow-up protocols for
common cancers such as prostate, bowel and lung cancer; further
research on cost-effectiveness of various follow-up protocols is
required, with a careful analysis of the potential and limitations of
primary care. Capacity and workforce issues are of particular
importance in developing recommendations involving transfer of
follow-up from surgical to GP settings, and should be incorporated
in future research.
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